Can more intensive therapy replace anxiety meds for kids?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Ages 7-17 years (inclusive at time of consent/assent) 2. Primary Diagnostic and Statistical Manual, 5th Edition (DSM-5) diagnosis of separation anxiety disorder (SAD), and/or generalized anxiety disorder (GAD), and/or social anxiety disorder (SocAD) as determined by self-reported structured interview (MINI-KID) and confirmation by a study clinician. 3. Stable/treated Attention Deficit Hyperactivity Disorder (ADHD), combined or hyperactive impulsive subtypes 4. An available primary caretaker with ongoing patient contact who is legally able to provide consent 5. Medically cleared by a pediatric clinician including a negative urine pregnancy test for females of child-bearing age. Furthermore, female patients must agree to abstain from sexual activity or to use a reliable method of birth control as determined by pediatric clinician during the study. Exclusion Criteria: 1. Patients with the following lifetime psychiatric disorders: moderate to severe autism, bipolar disorder, schizophrenia, or schizoaffective disorder, history of intellectual disability 2. Primary Attention Deficit Hyperactivity Disorder (ADHD), combined or hyperactive impulsive subtypes 3. Major depressive disorder with greater severity than anxiety disorder requiring treatment not provided in PCAY 4. Obsessive Compulsive Disorder (OCD) only (no co-occurring SAD, SocAD or GAD) 5. Patients with a major medical illness that would interfere with participation in the study (e.g., complex, and evolving medical treatments, or require frequent hospitalizations). 6. Patients who are pregnant as indicated by a positive pregnancy test or are sexually active and not using effective birth control. 7. Patients who pose a significant and imminent risk to self or to others. 8. Patients who experienced minimal or no change an adequate dose of evidenced-based medication treatment or CBT for their anxiety disorder. (See medication and CBT exclusions below) 9. Patients or caregiver(s) who do not speak English or Spanish. All materials and treatments will be available in Spanish and English. 10. Children and adolescents with complex psychiatric needs that cannot be managed in primary care and community settings as determined by study local Principal Investigator (PI) and provider teams. Medication Exclusions Fluoxetine * 20 mg for at least 6 of 10 weeks in children \<12 year * 40 mg for at least 6 of 10 weeks in adolescents \>12 years Sertraline * 100 for at least 6 of 10 weeks in children \<12 years * 150 for at least 6 of 10 weeks in adolescents \>12 years Citalopram * 20 mg for at least 6 of 10 weeks in children \>12 years * 30 mg for at least 6 of 10 weeks adolescent \> 12 years Escitalopram * 10 mg for at least 6 of 10 weeks in children \<12 years * 20 mg for at least 6 of 10 weeks in adolescent \>12 years Fluvoxamine * 150 mg for at least 6 of 10 weeks in children \<12 years * 200 mg for at least 6 of 10 weeks in children \< 12 year CBT Exclusions Failed a previous trial of verified CBT for anxiety disorders within the previous year judged adequate by ≥12 exposure-based CBT sessions